MET and non-small cell lung carcinoma: To shed light on which treatment regimen is the most effective in this subset of patients, we retrospectively analyzed the clinical outcomes of 70 patients with EGFR-mutant NSCLC who acquired MET amplification during EGFR-TKI therapy and received any of the following three treatment regimens: crizotinib in combination with any EGFR-TKI (n = 38), crizotinib monotherapy (n = 10), or chemotherapy regimen (n = 22).